Serine synthesis influences tamoxifen response in ER+ human breast carcinoma

• Published in: Endocrine-related cancer Vol. 28; no. 1; pp. 27 - 37
• Main Authors: Metcalf, Stephanie, Petri, Belinda J, Kruer, Traci, Green, Benjamin, Dougherty, Susan, Wittliff, James L, Klinge, Carolyn M, Clem, Brian F
• Format: Journal Article
• Language: English
• Published: England Bioscientifica Ltd 01.01.2021; Society for Endocrinology & BioScientifica Ltd
• Subjects: Breast cancer; Breast carcinoma; Breast Neoplasms - drug therapy; Cell growth; Cell proliferation; Endocrine therapy; Enzymes; Estrogen receptors; Female; Humans; Patients; Phosphoglycerate dehydrogenase; Phosphoserine; Phosphoserine aminotransferase; Serine; Serine - metabolism; Tamoxifen; Tamoxifen - pharmacology; Tamoxifen - therapeutic use; Transfection; estrogen receptor-positive breast cancer; phosphoserine aminotransferase 1; endocrine resistance; tamoxifen; serine synthesis
• ISSN: 1351-0088; 1479-6821
• DOI: 10.1530/ERC-19-0510

Estrogen receptor-positive breast cancer (ER+ BC) is the most common form of breast carcinoma accounting for approximately 70% of all diagnoses. Although ER-targeted therapies have improved survival outcomes for this BC subtype, a significant proportion of patients will ultimately develop resistance to these clinical interventions, resulting in disease recurrence. Phosphoserine aminotransferase 1 (PSAT1), an enzyme within the serine synthetic pathway (SSP), has been previously implicated in endocrine resistance. Therefore, we determined whether expression of SSP enzymes, PSAT1 or phosphoglycerate dehydrogenase (PHGDH), affects the response of ER+ BC to 4-hydroxytamoxifen (4-OHT) treatment. To investigate a clinical correlation between PSAT1, PHGDH, and endocrine resistance, we examined microarray data from ER+ patients who received tamoxifen as the sole endocrine therapy. We confirmed that higher PSAT1 and PHGDH expression correlates negatively with poorer outcomes in tamoxifen-treated ER+ BC patients. Next, we found that SSP enzyme expression and serine synthesis were elevated in tamoxifen-resistant compared to tamoxifen-sensitive ER+ BC cells in vitro. To determine relevance to endocrine sensitivity, we modified the expression of either PSAT1 or PHGDH in each cell type. Overexpression of PSAT1 in tamoxifen-sensitive MCF-7 cells diminished 4-OHT inhibition on cell proliferation. Conversely, silencing of either PSAT1 or PHGDH resulted in greater sensitivity to 4-OHT treatment in LCC9 tamoxifen-resistant cells. Likewise, the combination of a PHGDH inhibitor with 4-OHT decreased LCC9 cell proliferation. Collectively, these results suggest that overexpression of serine synthetic pathway enzymes contribute to tamoxifen resistance in ER+ BC, which can be targeted as a novel combinatorial treatment option.